Travere Therapeutics (TVTX) Total Non-Current Liabilities (2011 - 2026)

Travere Therapeutics (TVTX) has 16 years of Total Non-Current Liabilities data on file, last reported at $447.1 million in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 12.11% year-over-year to $447.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $447.1 million (down 12.11% YoY) and the FY2025 annual result came in at $482.8 million, down 8.61% from the prior year.
• Total Non-Current Liabilities fell to $447.1 million in Q1 2026, from $482.8 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $620.3 million in Q4 2022 to a low of $447.1 million in Q1 2026.
• A 5-year average of $535.2 million and a median of $543.9 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities jumped 70.28% — and 2026, when it fell 12.11%.
• Tracing TVTX's Total Non-Current Liabilities over 5 years: stood at $620.3 million in 2022, then fell by 6.86% to $577.8 million in 2023, then slipped by 8.57% to $528.3 million in 2024, then slipped by 8.61% to $482.8 million in 2025, then decreased by 7.39% to $447.1 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $447.1 million (Q1 2026), $482.8 million (Q4 2025), and $459.1 million (Q3 2025), per Business Quant data.